Mercado M, Abreu C, Vergara-López A, et al. - Given that acromegaly registries constitute a valuable source of therapeutic outcome information in real-life, researchers sought to analyze surgical and pharmacological outcomes in the Mexican Acromegaly Registry (MAR). Data from the MAR informatic platform were extracted. In total, 650 surgical outcomes have been analyzed (94.6% transsphenoidal). Data reported that surgical remission, defined by a postoperative post-glucose GH < 1 ng/mL and an IGF-1 < 1.2 x ULN, was achieved in 40.15%, while 44.15% remained biochemically active. Persistently active disease following surgery was significantly linked to harboring an invasive macroadenoma, a basal GH > 10 ng/mL and/or an IGF-1 > 2 x ULN at diagnosis upon bivariate and multivariate analysis. Surgical and pharmacological results in acromegaly depend heavily on the size of the tumor/invasiveness as well as on the degree of hypersomatotropinemia.